Edition:
United States

Halozyme Therapeutics Inc (HALO.O)

HALO.O on Nasdaq

17.72USD
18 Oct 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$17.72
Open
--
Day's High
--
Day's Low
--
Volume
563
Avg. Vol
1,258,495
52-wk High
$18.43
52-wk Low
$8.18

Latest Key Developments (Source: Significant Developments)

Halozyme licenses new Enhanze target for $30 mln upfront payment
Thursday, 14 Sep 2017 07:06am EDT 

Sept 14 (Reuters) - Halozyme Therapeutics Inc ::Halozyme licenses new enhanze target for $30 million upfront payment, future milestones and royalties.Halozyme therapeutics-co will receive initial $30 million with potential to earn additional payments of up to $160 million, subject to certain milestones​.Halozyme therapeutics-licensed its enhanze drug-delivery technology to roche for exclusive development of an undisclosed therapeutic target.  Full Article

Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology
Thursday, 14 Sep 2017 06:59am EDT 

Sept 14 (Reuters) - Bristol-Myers Squibb Co :Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology.Bristol-Myers Squibb Co - ‍Halozyme to receive $105 million upfront payment, plus future milestones and royalties​.Bristol-Myers Squibb Co - ‍Halozyme to receive $105 million upfront payment, plus future milestones and royalties​.Bristol-Myers Squibb Co - ‍provides Bristol-Myers Squibb access to enhanze technology for up to 11 targets​.Bristol-Myers Squibb Co - ‍collaboration may extend to a maximum of 11 targets​.Bristol-Myers Squibb Co - ‍for Bristol-Myers Squibb, transaction is expected to be dilutive to non-gaap earnings per share in 2017​.Bristol-Myers - ‍Halozyme has potential to earn milestone payments of upto $160 million for each nominated collaboration targets,additional milestone payments​.Bristol-Myers Squibb says ‍for co, deal is expected to be dilutive to non-GAAP earnings per share in 2017 and 2018 by approximately $0.01​.Bristol-Myers Squibb Co - ‍for co, deal is expected to be dilutive to non-GAAP earnings per share by about $0.05 in 2019​.  Full Article

Halozyme reports Q2 loss per share $0.23
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Halozyme Therapeutics Inc -:Halozyme reports second quarter 2017 results.Q2 loss per share $0.23.Q2 revenue $33.8 million versus I/B/E/S view $31.8 million.Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $115 million to $130 million.Halozyme Therapeutics Inc sees 2017 net revenue of $115 million to $130 million.Halozyme Therapeutics Inc sees 2017 operating cash burn of $75 million to $85 million.Halozyme Therapeutics Inc sees 2017 year-end cash balance of $245 million to $260 million.FY2017 revenue view $132.1 million -- Thomson Reuters I/B/E/S.  Full Article

Halozyme announces initiation of clinical trial collaboration
Thursday, 13 Jul 2017 08:30am EDT 

July 13 (Reuters) - Halozyme Therapeutics Inc ::Initiation of clinical trial collaboration evaluating Halozyme's pegph20 in combination with anti-PDL1 immunotherapy.Halozyme Therapeutics says combination will be tested in patients with previously treated metastatic pancreatic ductal adenocarcinoma.Says ‍study is sponsored by and funded by Genentech​.  Full Article

Halozyme Therapeutics, unit entered into first amendment to amended, restated lease with BMR-11388 Sorrento Valley Road
Wednesday, 5 Jul 2017 04:22pm EDT 

July 5 (Reuters) - Halozyme Therapeutics Inc ::Halozyme Therapeutics Inc - co, unit entered into a first amendment to amended and restated lease with bmr-11388 sorrento valley road lp.Halozyme Therapeutics Inc - co, unit also entered into a first amendment to lease with bmr-sorrento plaza llc - sec filing.Halozyme Therapeutics Inc - lease amendments effectively extend company's tenancy at these facilities for an additional five years.Halozyme Therapeutics Inc - 11388 lease amendment extension commences on January 15, 2018 and expires on january 14, 2023.  Full Article

Halozyme Therapeutics prices public offering of common stock
Thursday, 18 May 2017 09:30pm EDT 

May 18 (Reuters) - Halozyme Therapeutics Inc :Halozyme Therapeutics prices public offering of common stock.Priced previously announced underwritten public offering of 10 million shares of its common stock at $12.50 per share.  Full Article

Halozyme Therapeutics announces public offering of common stock
Thursday, 18 May 2017 04:05pm EDT 

May 18 (Reuters) - Halozyme Therapeutics Inc :Halozyme Therapeutics announces public offering of common stock.Commenced an underwritten public offering of $100 million of shares of its common stock.Halozyme intends to use net proceeds from this offering to fund continued development of its PEGPH20 oncology program.  Full Article

Halozyme reports first quarter 2017 financial results
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Halozyme Therapeutics Inc ::Halozyme reports first quarter 2017 financial results.Q1 loss per share $0.26.Q1 revenue $29.6 million versus I/B/E/S view $30.9 million.Q1 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $115 million to $130 million.Says for 2017, company reiterated its financial guidance of net revenue of $115 million to $130 million.FY2017 revenue view $132.6 million -- Thomson Reuters I/B/E/S.  Full Article

Halozyme Therapeutics Q4 loss per share $0.21
Tuesday, 28 Feb 2017 04:05pm EST 

Halozyme Therapeutics Inc : Says for 2017, company reiterated and updated cash portions of its financial guidance . Sees 2017 operating expenses of $240 million to $250 million . Sees 2017 operating cash burn of $75 million to $85 million . FY2017 revenue view $131.6 million -- Thomson Reuters I/B/E/S . Halozyme reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.21 . Q4 revenue $39 million versus I/B/E/S view $38.4 million . Q4 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S .Sees FY 2017 revenue $115 million to $130 million.  Full Article

First Eagle Investment Management LLC reports a 5.94 pct passive stake in Halozyme Therapeutics as of Dec 31 - SEC Filing
Monday, 6 Feb 2017 05:02pm EST 

Halozyme Therapeutics Inc :First Eagle Investment Management LLC reports a 5.94 percent passive stake in Halozyme Therapeutics Inc as of December 31, 2016 - SEC Filing.  Full Article

Photo

Halozyme to license drug delivery tech to Roche, Bristol-Myers

U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.